Insmed Incorporated
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About INSM
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.
CEOWilliam H. Lewis
CEOWilliam H. Lewis
Employees1,271
Employees1,271
HeadquartersBridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded1988
Founded1988
Employees1,271
Employees1,271
INSM Key Statistics
Market cap13.02B
Market cap13.02B
Price-Earnings ratio-13.41
Price-Earnings ratio-13.41
Dividend yield—
Dividend yield—
Average volume2.09M
Average volume2.09M
High today$74.69
High today$74.69
Low today$71.57
Low today$71.57
Open price$73.30
Open price$73.30
Volume466.57K
Volume466.57K
52 Week high$84.91
52 Week high$84.91
52 Week low$21.92
52 Week low$21.92
INSM News
TipRanks 3d
Insmed assumed with an Overweight at Morgan StanleyMorgan Stanley analyst Maxwell Skor assumed coverage of Insmed (INSM) with an Overweight rating and $90 price target The firm views Insmed as well-positioned to...
TipRanks 4d
Insmed price target raised to $110 from $105 at UBSUBS raised the firm’s price target on Insmed (INSM) to $110 from $105 and keeps a Buy rating on the shares. Phase 2 data for treprostinil palmitil inhalation po...
Analyst ratings
100%
of 18 ratingsBuy
100%
Hold
0%
Sell
0%